A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells

Cancer Biology and Therapy

Volumn 8, Issue 18, 2009, Pages 1722-1728

  Zhu, Hua ^a   Evans, Brad ^a   O'Neill, Peter ^a   Ren, Xingcong ^a   Xu, Zude ^a   Hait, William N ^a   Yang, Jin Ming ^a  

^a NONE

Author keywords

Extracellular matrix metalloproteinase inducer; Matrix metalloproteinase; P53; Tumor progression

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD147 ANTIGEN; CHLOROQUINE; GELATINASE B; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; REGULATORY MECHANISM; UPREGULATION;

EID: 73249152867     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.18.9207     Document Type: Article

References (37)

1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
3. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19:697-702.
4. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61:2276-81.
5. Zhang W, Erkan M, Abiatari I, Giese NA, Felix K, Kayed H, et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther 2007; 6:218-27.
6. Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 2006; 4:371-7.
7. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003; 1:420-7.
8. Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM, et al. Upregulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007; 98:1767-74.
9. Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 2007; 98:1064-9.
10. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem 2006; 281:9719-27.
11. Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, Beeson C, et al. Hyaluronan, CD44 and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009; 69:1293-301.
12. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67:4182-9.
13. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, et al. Resveratrol inhibits EMMPRIN expression via p38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 2008; 374:517-21.
14. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
15. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007; 178:23-30.
16. Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 2006; 66:10671-6.
17. Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 2007; 26:3329-37.
18. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991; 46:31-6.
19. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 2000; 105:1261-7.
20. Yoneda K, Yokoyama T, Yamamoto T, Hatabe T, Osaki T. p53 gene mutations and p21 protein expression induced independently of p53, by TGFbeta and gamma-rays in squamous cell carcinoma cells. Eur J Cancer 1999; 35:278-83.
21. Nakanishi Y, Pei XH, Takayama K, Bai F, Izumi M, Kimotsuki K, et al. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. Am J Respir Cell Mol Biol 2000; 22:747-54.
22. ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism. Cell Cycle 2007; 6:1741-7.
23. Valbuena A, Vega FM, Blanco S, Lazo PA. p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol 2006; 26:4782-93.
24. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57:205-25.
25. Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 2003; 22:3645-54.
26. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57.
27. Marchal C, Haguenauer-Tsapis R, Urban-Grimal D. A PEST-like sequence mediates phosphorylation and efficient ubiquitination of yeast uracil permease. Mol Cell Biol 1998; 18:314-21.
28. Kornitzer D, Raboy B, Kulka RG, Fink GR. Regulated degradation of the transcription factor Gcn4. EMBO J 1994; 13:6021-30.
29. Fogarty MP, McCormack RM, Noonan J, Murphy D, Gowran A, Campbell VA. A role for p53 in the beta-amyloid-mediated regulation of the lysosomal system. Neurobiol Aging 2008; In Press.
30. Gowran A, Campbell VA. A role for p53 in the regulation of lysosomal permeability by delta 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. J Neurochem 2008; 105:1513-24.
31. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
32. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, Varmus HE. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 2005; 25:1228-37.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
34. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001; 158:1921-8.
35. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10:3422-8.
36. Roth MJ, Hu N, Johnson LL, Quon-Hang W, Ahnen DJ, Iwamoto M, et al. beta-Catenin splice variants and downstream targets as markers for neoplastic progression of esophageal cancer. Gene Chromosome Canc 2005; 44:423-8.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.